Selected research
Market Outlook & Growth Opportunities
Global Chickenpox (Varicella) Vaccine Market Outlook and Growth Opportunities 2026
Market perspective
The global Chickenpox (Varicella) Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Chickenpox (Varicella) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Chickenpox (Varicella) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Chickenpox (Varicella) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Chickenpox (Varicella) Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Chickenpox (Varicella) Vaccine market include Shanghai Institute, Merck & Co., GSK, Sanofi Pasteur, Keygen, Green Cross, Changsheng, Biken and BCHT, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Chickenpox (Varicella) Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Chickenpox (Varicella) Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Chickenpox (Varicella) Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chickenpox (Varicella) Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.
Chickenpox (Varicella) Vaccine Segment by Company
Shanghai Institute
Merck & Co.
GSK
Sanofi Pasteur
Keygen
Green Cross
Changsheng
Biken
BCHT
Chickenpox (Varicella) Vaccine Segment by Type
Monovalent Vaccine
Combination Vaccine
Chickenpox (Varicella) Vaccine Segment by Application
Kids Injection
Adults Injection
Chickenpox (Varicella) Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Chickenpox (Varicella) Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Chickenpox (Varicella) Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Chickenpox (Varicella) Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Chickenpox (Varicella) Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chickenpox (Varicella) Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Chickenpox (Varicella) Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chickenpox (Varicella) Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Chickenpox (Varicella) Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Chickenpox (Varicella) Vaccine industry.
Chapter 3: Detailed analysis of Chickenpox (Varicella) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Chickenpox (Varicella) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Chickenpox (Varicella) Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Monovalent Vaccine
- Combination Vaccine
Applications
- Kids Injection
- Adults Injection
Companies covered
- Shanghai Institute
- Merck & Co.
- GSK
- Sanofi Pasteur
- Keygen
- Green Cross
- Changsheng
- Biken
- BCHT
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Chickenpox (Varicella) Vaccine Sales Value (2021-2032)
- 1.2.2 Global Chickenpox (Varicella) Vaccine Sales Volume (2021-2032)
- 1.2.3 Global Chickenpox (Varicella) Vaccine Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Chickenpox (Varicella) Vaccine Market Dynamics
- 2.1 Chickenpox (Varicella) Vaccine Industry Trends
- 2.2 Chickenpox (Varicella) Vaccine Industry Drivers
- 2.3 Chickenpox (Varicella) Vaccine Industry Opportunities and Challenges
- 2.4 Chickenpox (Varicella) Vaccine Industry Restraints
3 Chickenpox (Varicella) Vaccine Market by Company
- 3.1 Global Chickenpox (Varicella) Vaccine Company Revenue Ranking in 2025
- 3.2 Global Chickenpox (Varicella) Vaccine Revenue by Company (2021-2026)
- 3.3 Global Chickenpox (Varicella) Vaccine Sales Volume by Company (2021-2026)
- 3.4 Global Chickenpox (Varicella) Vaccine Average Price by Company (2021-2026)
- 3.5 Global Chickenpox (Varicella) Vaccine Company Ranking (2024-2026)
- 3.6 Global Chickenpox (Varicella) Vaccine Company Manufacturing Base and Headquarters
- 3.7 Global Chickenpox (Varicella) Vaccine Company Product Type and Application
- 3.8 Global Chickenpox (Varicella) Vaccine Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Chickenpox (Varicella) Vaccine Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Chickenpox (Varicella) Vaccine Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Chickenpox (Varicella) Vaccine Market by Type
- 4.1 Chickenpox (Varicella) Vaccine Type Introduction
- 4.1.1 Monovalent Vaccine
- 4.1.2 Combination Vaccine
- 4.2 Global Chickenpox (Varicella) Vaccine Sales Volume by Type
- 4.2.1 Global Chickenpox (Varicella) Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Chickenpox (Varicella) Vaccine Sales Volume by Type (2021-2032)
- 4.2.3 Global Chickenpox (Varicella) Vaccine Sales Volume Share by Type (2021-2032)
- 4.3 Global Chickenpox (Varicella) Vaccine Sales Value by Type
- 4.3.1 Global Chickenpox (Varicella) Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Chickenpox (Varicella) Vaccine Sales Value by Type (2021-2032)
- 4.3.3 Global Chickenpox (Varicella) Vaccine Sales Value Share by Type (2021-2032)
5 Chickenpox (Varicella) Vaccine Market by Application
- 5.1 Chickenpox (Varicella) Vaccine Application Introduction
- 5.1.1 Kids Injection
- 5.1.2 Adults Injection
- 5.2 Global Chickenpox (Varicella) Vaccine Sales Volume by Application
- 5.2.1 Global Chickenpox (Varicella) Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Chickenpox (Varicella) Vaccine Sales Volume by Application (2021-2032)
- 5.2.3 Global Chickenpox (Varicella) Vaccine Sales Volume Share by Application (2021-2032)
- 5.3 Global Chickenpox (Varicella) Vaccine Sales Value by Application
- 5.3.1 Global Chickenpox (Varicella) Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Chickenpox (Varicella) Vaccine Sales Value by Application (2021-2032)
- 5.3.3 Global Chickenpox (Varicella) Vaccine Sales Value Share by Application (2021-2032)
6 Chickenpox (Varicella) Vaccine Regional Sales and Value Analysis
- 6.1 Global Chickenpox (Varicella) Vaccine Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Chickenpox (Varicella) Vaccine Sales by Region (2021-2032)
- 6.2.1 Global Chickenpox (Varicella) Vaccine Sales by Region: 2021-2026
- 6.2.2 Global Chickenpox (Varicella) Vaccine Sales by Region (2027-2032)
- 6.3 Global Chickenpox (Varicella) Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Chickenpox (Varicella) Vaccine Sales Value by Region (2021-2032)
- 6.4.1 Global Chickenpox (Varicella) Vaccine Sales Value by Region: 2021-2026
- 6.4.2 Global Chickenpox (Varicella) Vaccine Sales Value by Region (2027-2032)
- 6.5 Global Chickenpox (Varicella) Vaccine Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Chickenpox (Varicella) Vaccine Sales Value (2021-2032)
- 6.6.2 North America Chickenpox (Varicella) Vaccine Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Chickenpox (Varicella) Vaccine Sales Value (2021-2032)
- 6.7.2 Europe Chickenpox (Varicella) Vaccine Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Chickenpox (Varicella) Vaccine Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Chickenpox (Varicella) Vaccine Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Chickenpox (Varicella) Vaccine Sales Value (2021-2032)
- 6.9.2 South America Chickenpox (Varicella) Vaccine Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Chickenpox (Varicella) Vaccine Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Chickenpox (Varicella) Vaccine Sales Value Share by Country, 2025 VS 2032
7 Chickenpox (Varicella) Vaccine Country-level Sales and Value Analysis
- 7.1 Global Chickenpox (Varicella) Vaccine Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Chickenpox (Varicella) Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Chickenpox (Varicella) Vaccine Sales by Country (2021-2032)
- 7.3.1 Global Chickenpox (Varicella) Vaccine Sales by Country (2021-2026)
- 7.3.2 Global Chickenpox (Varicella) Vaccine Sales by Country (2027-2032)
- 7.4 Global Chickenpox (Varicella) Vaccine Sales Value by Country (2021-2032)
- 7.4.1 Global Chickenpox (Varicella) Vaccine Sales Value by Country (2021-2026)
- 7.4.2 Global Chickenpox (Varicella) Vaccine Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.9.2 France Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.16.2 China Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.19.2 India Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Chickenpox (Varicella) Vaccine Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Chickenpox (Varicella) Vaccine Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Chickenpox (Varicella) Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Shanghai Institute
- 8.1.1 Shanghai Institute Company Information
- 8.1.2 Shanghai Institute Business Overview
- 8.1.3 Shanghai Institute Chickenpox (Varicella) Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Shanghai Institute Chickenpox (Varicella) Vaccine Product Portfolio
- 8.1.5 Shanghai Institute Recent Developments
- 8.2 Merck & Co.
- 8.2.1 Merck & Co. Company Information
- 8.2.2 Merck & Co. Business Overview
- 8.2.3 Merck & Co. Chickenpox (Varicella) Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Merck & Co. Chickenpox (Varicella) Vaccine Product Portfolio
- 8.2.5 Merck & Co. Recent Developments
- 8.3 GSK
- 8.3.1 GSK Company Information
- 8.3.2 GSK Business Overview
- 8.3.3 GSK Chickenpox (Varicella) Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.3.4 GSK Chickenpox (Varicella) Vaccine Product Portfolio
- 8.3.5 GSK Recent Developments
- 8.4 Sanofi Pasteur
- 8.4.1 Sanofi Pasteur Company Information
- 8.4.2 Sanofi Pasteur Business Overview
- 8.4.3 Sanofi Pasteur Chickenpox (Varicella) Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Sanofi Pasteur Chickenpox (Varicella) Vaccine Product Portfolio
- 8.4.5 Sanofi Pasteur Recent Developments
- 8.5 Keygen
- 8.5.1 Keygen Company Information
- 8.5.2 Keygen Business Overview
- 8.5.3 Keygen Chickenpox (Varicella) Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Keygen Chickenpox (Varicella) Vaccine Product Portfolio
- 8.5.5 Keygen Recent Developments
- 8.6 Green Cross
- 8.6.1 Green Cross Company Information
- 8.6.2 Green Cross Business Overview
- 8.6.3 Green Cross Chickenpox (Varicella) Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.6.4 Green Cross Chickenpox (Varicella) Vaccine Product Portfolio
- 8.6.5 Green Cross Recent Developments
- 8.7 Changsheng
- 8.7.1 Changsheng Company Information
- 8.7.2 Changsheng Business Overview
- 8.7.3 Changsheng Chickenpox (Varicella) Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.7.4 Changsheng Chickenpox (Varicella) Vaccine Product Portfolio
- 8.7.5 Changsheng Recent Developments
- 8.8 Biken
- 8.8.1 Biken Company Information
- 8.8.2 Biken Business Overview
- 8.8.3 Biken Chickenpox (Varicella) Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Biken Chickenpox (Varicella) Vaccine Product Portfolio
- 8.8.5 Biken Recent Developments
- 8.9 BCHT
- 8.9.1 BCHT Company Information
- 8.9.2 BCHT Business Overview
- 8.9.3 BCHT Chickenpox (Varicella) Vaccine Sales, Value and Gross Margin (2021-2026)
- 8.9.4 BCHT Chickenpox (Varicella) Vaccine Product Portfolio
- 8.9.5 BCHT Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Chickenpox (Varicella) Vaccine Value Chain Analysis
- 9.1.1 Chickenpox (Varicella) Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Chickenpox (Varicella) Vaccine Sales Mode & Process
- 9.2 Chickenpox (Varicella) Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Chickenpox (Varicella) Vaccine Distributors
- 9.2.3 Chickenpox (Varicella) Vaccine Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst